<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01259388</url>
  </required_header>
  <id_info>
    <org_study_id>CDA2-003-10S</org_study_id>
    <nct_id>NCT01259388</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Lithium in Progressive Multiple Sclerosis</brief_title>
  <official_title>A Pilot Trial of Lithium in Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether lithium carbonate is safe, well-tolerated,
      and effective at treating progressive forms of multiple sclerosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change in brain parenchymal fraction</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of new gadolinium-enhancing brain MRI lesions</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and volume of new T2-weighted brain MRI lesions</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and volume of new T1-weighted hypointense brain MRI lesions</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One year's treatment of standard therapy plus lithium followed by one year of standard therapy without lithium.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One year's treatment with standard therapy followed by one year of standard therapy plus lithium.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium Carbonate</intervention_name>
    <description>Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of a progressive subtype of multiple sclerosis by revised 2005 McDonald
             Criteria.

          -  EDSS of 3.0-6.5

          -  Ages 30-65

          -  Must be mentally capable of providing informed consent and following study guidelines.

        Exclusion Criteria:

          -  Relapse or steroid treatment within 1 month of trial entry.

          -  Any current or previous treatment with mitoxantrone, azathioprine, methotrexate,
             mycophenolate, cyclophosphamide, or any experimental therapy.

          -  Women who are pregnant, wishing to become pregnant in the coming 30 months, or are
             breastfeeding.

          -  Sexually active women unwilling to use reliable contraception (oral contraceptives,
             condom, IUD).

          -  Patients with known kidney dysfunction or creatinine &gt;1.4; known cardiac arrhythmia or
             significant conduction abnormality on EKG; uncontrolled thyroid disease or TSH &gt;20%
             above the upper limit of normal; uncontrolled psoriasis, HIV, or any other severe
             medical condition.

          -  Patients with a history of unstable psychiatric illness or active severe depression.

          -  Patients with a history of seizure.

          -  Concurrent use of any of the following medications: Antipsychotics, diuretics,
             digoxin, or iodide salts.

          -  Use of non-steroidal anti-inflammatory drugs (NSAIDs) 5 or more days a week.

          -  Patients with a history of substance abuse in the past year.

          -  Patients sensitive to gadolinium, or who are unable to undergo the required number of
             MRI scans.

          -  Unable to speak or understand sufficient English to consent or complete study
             procedures.

          -  Patients unable or unwilling to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John R Rinker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Birmingham VA Medical Center, Birmingham, AL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham VA Medical Center, Birmingham, AL</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirklin Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2010</study_first_submitted>
  <study_first_submitted_qc>December 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2010</study_first_posted>
  <last_update_submitted>March 30, 2016</last_update_submitted>
  <last_update_submitted_qc>March 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Lithium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

